Human Insulin Market- Global Report on Human Insulin Industry, 2020

Human Insulin Market - Global Study on Human Insulin Industry : Asia
Pacific to Witness fastest Growth by 2020
Persistence Market Research
Human Insulin Market Will Reach
US$49,197.3 million in 2020: Persistence
Market Research
Persistence Market Research 1

Persistence Market Research Released New Market Report “Global Market Study on Human
Insulin: Asia Pacific to Witness fastest Growth by 2020,” the global human insulin
market was valued at USD 24,332.6 million in 2014 and was expected to grow at a CAGR of
12.4% from 2014 to 2020, to reach an estimated value of USD 49,197.3 million in 2020.
Browse the full Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth
by 2020 report at http://www.persistencemarketresearch.com/market-
research/human-insulin-market.asp
Globally, the human insulin market is witnessing significant growth due to increasing
prevalence of diabetes and increasing awareness among people about diabetes care. In
addition, technological advancements in insulin delivery devices and increasing prevalence of
lifestyle related disorders such as obesity are also driving the growth of the market. However,
uneven pricing and limited access to human insulin in emerging countries such as Brazil, India,
and China are inhibiting the growth of the human insulin market. In addition, strict regulatory
requirements for drug approval are also restraining the growth of the market. The global
human insulin market was anticipated to grow from an estimated USD 24,332.6 million in 2014
to USD 49,197.3 million in 2020 at a CAGR of 12.4% during the forecast period.
In North America, increasing prevalence of diabetes with growing age and availability of
advanced human insulin infusion devices are driving the use of human insulin in the market.
In addition, increasing prevalence of lifestyle associated disorders such as obesity is also
boosting the growth of the human insulin market in this region. For instance, according to the
Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health
institute, over one-third children and adolescents were obese in 2012 in the U.S.
In Europe, the human insulin market is driven by rising aging population and increasing
prevalence of diabetes. In addition, in Germany the market is evolving due to rising prevalence
of diabetes and increasing awareness among people about diabetes care. However, in Asia-
Pacific the growth for human insulin is much higher than developed countries due to increasing
prevalence of diabetes and increasing government initiatives for improving healthcare.
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co.,
Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company,
GlaxoSmithKline Plc and Oramed Pharmaceuticals, Inc. are some of the major players in human
insulin market.

The human insulin market is segmented as follows:
Human insulin market, by type
• Traditional human insulin
• Modern human insulin
Traditional human insulin market, by type
• Short acting human insulin
• Intermediate acting human insulin
• Premixed human insulin
Modern human insulin market, by type
• Rapid-acting human insulin
• Long-acting human insulin
• Premixed human insulin
Human insulin market, by disease
• Type 1 diabetes
• Type 2 diabetes
Traditional human insulin market, by brand
• Humulin
• Insuman
• Others
Modern human insulin market, by brand
• Lantus
• Novolog
• Humalog
• Levemir

• Novomix
• Apidra
• Others
Human insulin market, by geography
• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• The U.K.
• Asia-Pacific
• Japan
• China
• India
• Rest of the World (RoW)
Market History:
Globally, the human insulin market is witnessing significant growth due to increasing prevalence of
diabetes and obesity. In addition, increasing R&D investments in drug discovery and development and
rising awareness about diabetes are also driving the growth of the market. However, uneven pricing and
limited access to human insulin in emerging countries and strict regulatory requirement for drug approval
inhibits the growth of the market. The global human insulin market was anticipated to grow from an
estimated USD 24,332.6 million in 2014 to USD 49,197.3 million by 2020 at a CAGR of 12.4% during the
forecast period.
North America has the largest market and Asia-Pacific has the fastest growing market for human insulin.
In terms of type of human insulin, modern human insulin represents the largest and fastest growing
segment of this market.
Modern human insulin provides effective results compare to traditional human insulin. Dosages and
duration of modern human insulin vary from person to person, as insulin requirement differs from person

to person. Modern human insulin was estimated at USD 19,526.8 million in 2014 and was expected to
reach USD 40,987.1 million by 2020, growing at a CAGR of 13.2% during the forecast period.
Some of the major players in the human insulin market are Novo Nordisk A/S, Eli Lilly and Company,
Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc.,
Wockhardt and others.
Table of Content
Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology
1.3 Assumptions
Chapter 2 Market Synopsis
Chapter 3 Porter’s Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry

Chapter 4 Industry Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Growing prevalence of diabetes
4.2.2 Technological advancements in human insulin delivery devices
4.2.3 Increasing awareness among people towards diabetes care
4.3 Impact Analysis of Market Drivers
4.4 Market Restraints
4.4.1 Uneven pricing and limited access to human insulin in emerging countries
4.4.2 Strict regulatory requirements for drug approval
4.5 Impact Analysis of Market Restraints
4.6 Market Trends
4.6.1 Increasing usage of insulin pens for administration of human insulin
Chapter 5 Global Market Size and Forecast
Chapter 6 Market Size and Forecast by Type
6.1 Traditional Human Insulin
6.2 Modern Human Insulin
Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type
7.1 Short-acting Human Insulin
7.2 Intermediate-acting Human Insulin
7.3 Premixed Human Insulin
Chapter 8 Market Size and Forecast of Modern Human Insulin by Type
8.1 Rapid-acting Human Insulin
8.2 Long-acting Human Insulin
8.3 Premixed Human Insulin
Chapter 9 Market Size and Forecast by Disease

9.1 Type 1 Diabetes
9.2 Type 2 Diabetes
Chapter 10 Market Size and Forecast by Brand
10.1 Traditional Human Insulin Brand
10.2 Modern Human Insulin Brand
Chapter 11 Market Size and Forecast by Geography
11.1 North America
11.1.1 Scenario in the U.S.
11.1.2 Scenario in Canada
11.2 Europe
11.2.1 Scenario in Germany
11.2.2 Scenario in France
11.2.3 Scenario in the U.K.
11.3 Asia Pacific
11.3.1 Scenario in Japan
11.3.2 Scenario in China
11.3.3 Scenario in India
Chapter 12 Pipeline Drugs for Diabetes Treatment
12.1 Drugs Under Development for Diabetes Treatment
Chapter 13 Competitive Scenario
13.1 Competitive Benchmarking
Chapter 14 Company Profiles
14.1 Novo Nordisk A/S
14.1.1 Company overview
14.1.2 Products and services
14.1.3 Financial performance
14.1.4 Key developments

14.2 Eli Lilly and Company
14.3 Sanofi
14.4 Biocon
14.5 Tonghua Dongbao Pharmaceutical Co., Ltd.
14.6 ADOCIA
14.7 Wockhardt
14.8 Julphar

14.9 Merck & Co., Inc.
14.10 Pfizer, Inc.
14.11 Bristol-Myers Squibb Company
14.12 GlaxoSmithKline Plc
14.13 Oramed Pharmaceuticals, Inc.

List of Tables
TABLE 1 Market snapshot: Human insulin market, 2014 and 2020
TABLE 2 Drivers for human insulin market: Impact analysis
TABLE 3 Restraints for human insulin market: Impact analysis
TABLE 4 Global human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 5 Global human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 6 Global human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 7 Global human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 8 Global traditional human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 9 Global traditional human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 10 Global modern human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 11 Global modern human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 12 Global short-acting human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 13 Global short-acting human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 14 Global intermediate-acting human insulin market size, by region, 2010 – 2013 (USD
million)
TABLE 15 Global intermediate-acting human insulin market size, by region, 2014 – 2020 (USD
million)
TABLE 16 Global premixed human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 18 Global rapid-acting human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 19 Global rapid-acting human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 20 Global long-acting human insulin market size, by region, 2010 – 2013 (USD million)
TABLE 21 Global long-acting human insulin market size, by region, 2014 – 2020 (USD million)
TABLE 24 Global type 1 diabetes human insulin market size, by region, 2010 – 2013 (USD
million)
million)

million)
million)
TABLE 28 Global traditional human insulin market size, by brand, 2010 – 2013 (USD million)
TABLE 29 Global traditional human insulin market size, by brand, 2014 – 2020 (USD million)
TABLE 30 Global modern human insulin market size, by brand, 2010 – 2013 (USD million)
TABLE 31 Global modern human insulin market size, by brand, 2014 – 2020 (USD million)
TABLE 32 The North American human insulin market size, by country, 2010 – 2013 (USD
million)
TABLE 33 The North American human insulin market size, by country, 2014 – 2020 (USD
million)
TABLE 34 The U.S. human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 35 The U.S. human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 36 The U.S. traditional human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 37 The U.S. traditional human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 38 The U.S. modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 39 The U.S. modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 40 The Canadian human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 41 The Canadian human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 42 The Canadian traditional human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 43 The Canadian traditional human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 44 The Canadian modern human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 45 The Canadian modern human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 46 The European human insulin market size, by country, 2010 – 2013 (USD million)
TABLE 47 The European human insulin market size, by country, 2014 – 2020 (USD million)
TABLE 48 The German human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 49 The German human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 50 The German traditional human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 51 The German traditional human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 52 The German modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 53 The German modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 54 The French human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 55 The French human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 56 The French traditional human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 57 The French traditional human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 58 The French modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 59 The French modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 60 The U.K. human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 61 The U.K. human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 62 The U.K. traditional human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 63 The U.K. traditional human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 64 The U.K. modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 65 The U.K. modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 66 The Asia Pacific human insulin market size, by country, 2010 – 2013 (USD million)
TABLE 67 The Asia Pacific human insulin market size, by country, 2014 – 2020 (USD million)
TABLE 68 The Japanese human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 69 The Japanese human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 70 The Japanese traditional human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 71 The Japanese traditional human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 72 The Japanese modern human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 73 The Japanese modern human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 74 The Chinese human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 75 The Chinese human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 76 The Chinese traditional human insulin market size, by type, 2010 – 2013 (USD
million)
TABLE 77 The Chinese traditional human insulin market size, by type, 2014 – 2020 (USD
million)
TABLE 78 The Chinese modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 79 The Chinese modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 80 The Indian human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 81 The Indian human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 82 The Indian traditional human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 83 The Indian traditional human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 84 The Indian modern human insulin market size, by type, 2010 – 2013 (USD million)
TABLE 85 The Indian modern human insulin market size, by type, 2014 – 2020 (USD million)
TABLE 86 Major pipeline drugs for diabetes treatment
TABLE 87 Major product segments of Novo Nordisk A/S
TABLE 88 Major product segments of Eli Lilly and Company
TABLE 89 Major product categories of Sanofi
TABLE 90 Major product categories of Biocon
TABLE 91 Major product categories of Tonghua Dongbao Pharmaceutical Co., Ltd.
TABLE 92 Major product categories of Adocia
TABLE 93 Major product categories of Wockhardt
TABLE 94 Major product categories of Julphar
TABLE 95 Major product categories of Merck & Co., Inc.
TABLE 96 Major product categories of Pfizer, Inc.
TABLE 97 Major product categories of Bristol-Myers Squibb Company
TABLE 98 Major product categories of GlaxoSmithKline Plc
TABLE 99 Major product categories of Oramed Pharmaceuticals, Inc.
List of Figures
FIG. 1 Human insulin market: Porter’s five forces analysis
FIG. 1 Major types of human insulin
FIG. 2 Major types of insulin delivery devices

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010 and
2030 (million)
FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015
(%)
FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015
(%)
FIG. 6 Global human insulin market share, by region, by value, 2013
FIG. 7 Global human insulin market share, by type, by value, 2013
FIG. 8 Global traditional human insulin market share, by region, by value, 2013
FIG. 9 Global modern human insulin market share, by region, by value, 2013
FIG. 10 Global short-acting human insulin market share, by region, by value, 2013
FIG. 11 Global intermediate-acting human insulin market share, by region, by value, 2013
FIG. 12 Global premixed human insulin market share, by region, by value, 2013
FIG. 13 Global rapid-acting human insulin market share, by region, by value, 2013
FIG. 14 Global long-acting human insulin market share, by region, by value, 2013
FIG. 15 Global premixed human insulin market share, by region, by value, 2013
FIG. 16 Global type 1 diabetes human insulin market share, by region, by value, 2013
FIG. 17 Global type 2 diabetes human insulin market share, by region, by value, 2013
FIG. 18 Global traditional human insulin market share, by brand, by value, 2013
FIG. 19 Global modern human insulin market share, by brand, by value, 2013
FIG. 20 The North American human insulin market share, by country, by value, 2013
FIG. 21 The U.S. human insulin market share, by type, by value, 2013
FIG. 22 The U.S. traditional human insulin market share, by type, by value, 2013
FIG. 23 The U.S. modern human insulin market share, by type, by value, 2013
FIG. 24 The Canadian human insulin market share, by type, by value, 2013
FIG. 25 The Canadian traditional human insulin market share, by type, by value, 2013
FIG. 26 The Canadian modern human insulin market share, by type, by value, 2013
FIG. 27 The European human insulin market share, by country, by value, 2013
FIG. 28 The German human insulin market share, by type, by value, 2013
FIG. 29 The German traditional human insulin market share, by type, by value, 2013
FIG. 30 The German modern human insulin market share, by type, by value, 2013
FIG. 31 The French human insulin market share, by type, by value, 2013

FIG. 32 The French traditional human insulin market share, by type, by value, 2013
FIG. 33 The French modern human insulin market share, by type, by value, 2013
FIG. 34 The U.K. human insulin market share, by type, by value, 2013
FIG. 35 The U.K. traditional human insulin market share, by type, by value, 2013
FIG. 36 The U.K. modern human insulin market share, by type, by value, 2013
FIG. 37 The Asia Pacific human insulin market share, by country, by value, 2013
FIG. 38 The Japanese human insulin market share, by type, by value, 2013
FIG. 39 The Japanese traditional human insulin market share, by type, by value, 2013
FIG. 40 The Japanese modern human insulin market share, by type, by value, 2013
FIG. 41 The Chinese human insulin market share, by type, by value, 2013
FIG. 42 The Chinese traditional human insulin market share, by type, by value, 2013
FIG. 43 The Chinese modern human insulin market share, by type, by value, 2013
FIG. 44 The Indian human insulin market share, by type, by value, 2013
FIG. 45 The Indian traditional human insulin market share, by type, by value, 2013
FIG. 46 The Indian modern human insulin market share, by type, by value, 2013
FIG. 47 Competitive benchmarking of human insulin manufacturing companies
FIG. 48 Novo Nordisk’s net sales and net profit, 2011 – 2013 (USD million)
FIG. 49 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million)
FIG. 50 Sanofi’s net sales and net income, 2011 – 2013 (USD million)
FIG. 51 Biocon’s revenue and profit, 2012 – 2014 (USD million)
FIG. 52 Tonghua Dongbao Pharmaceutical Co., Ltd.’s total revenue and net income, 2011 –
2013 (USD million)
FIG. 53 Wockhardt’s revenue and net income, 2011 – 2013 (USD million)
FIG. 54 Julphar’s sales and profit, 2011 – 2013 (USD million)
FIG. 55 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)
FIG. 56 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)
FIG. 57 Bristol-Myers Squibb Company’s total revenue and net earnings, 2011 – 2013 (USD
million)
FIG. 58 GlaxoSmithKline Plc’s turnover and profit, 2011 – 2013 (USD million)

About Us:
Persistence Market Research is a global market research firm specializing- syndicated research,
custom research, and consulting services
At Persistence Market Research (PMR), we are in the business of accelerating your business. As a full-
service market research firm, we stand committed to bringing more accuracy and speed to your business
decisions. From ready-to-purchase market research reports to customized global research solutions, our
engagement models are highly flexible without compromising on our deep-seated research values. Briefly
stated, our mission is to give you access to forecasts and trends analyses that put you on the path to
profitability.
PMR’s Services Go Beyond Gleaning Data
Most enterprises believe that IT and databases are enough to make an accurate decision. While we do
not dispute that, consider this: How long does it take to make an accurate and strategic million-dollar
decision? We strive to deliver both even with demanding deadlines.
Contact Us:
Addie Thomes
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Twitter: https://twitter.com/addiethomes
Blog: http://persistencemarketresearchblog.wordpress.com/

Human Insulin Market- Global Report on Human Insulin Industry, 2020

Recommandé

Recommandé

Contenu connexe

Dernier

Dernier (20)

En vedette

En vedette (20)

Human Insulin Market- Global Report on Human Insulin Industry, 2020